Thrombin Generation Test (TGT) & Rotational Thromboelastography (ROTEM™) and its use in assessing Severe Haemophilia A phenotype The classification and.

Slides:



Advertisements
Similar presentations
Basic coagulation techniques and Quality control issues
Advertisements

General Approach in Investigation of Haemostasis
A Multi-Laboratory Evaluation of a Chromogenic Factor X Assay for Monitoring Oral Anticoagulation Therapy DL McGlasson 1*; PN Shaklee 2; 1 59 th Clinical.
1 >> How to handle samples for coagulation analyses Anne-Mette Hvas Department of Clinical Biochemistry Center for Haemophilia and Thrombosis Aarhus University.
Tests of Hemostasis Path 430/826 David Lillicrap Department of Pathology and Molecular Medicine Queen’s University, Kingston, Canada.
Potential of the Factor Xa Inhibitor Rivaroxaban for the Anticoagulation Management of Patients with Heparin-Induced Thrombocytopenia Jeanine M. Walenga,
TACTIC PROJECT 2: THE ROLE OF FACTOR XI IN TIC LEAD INVESTIGATOR: SAULIUS BUTENAS (UNIVERSITY OF VERMONT) CO-INVESTIGATOR: JAMES H MORRISSEY (UNIVERSITY.
Week 6: Secondary Hemostasis Plasmatic factors Plasmatic factors Intrinsic pathway Intrinsic pathway Extrinsic pathway Extrinsic pathway Specimen Specimen.
One Stage Factor V Assay
Hemostasis, platelets and Blood management Julie Wegner, PhD, CP Midwestern University Glendale, AZ.
XGenCloud. Cloud service intended for automatic interpretation of genetic tests results, allows to form detailed genetic conclusion. Cloud service intended.
MLAB Coagulation Keri Brophy-Martinez
Printed by Prevalence of Heparin in Samples Submitted for Lupus Anticoagulant Testing Nikhil A. Sangle MD FRCPath 1,3, George M.
Basic Clinician Training Module 2
Measurement of Clopidogrel Resistance by ADP-Inhibition Does Not Reflect the Benefit of Clopidogrel on Overall Thrombotic Status Dr Diana A Gorog Consultant.
Understanding the scientific literature (Reading and evaluation of a research paper) Prof David Lane Department of Haematology Hammersmith Hospital Campus.
  The prothrombin time is therefore the time required for the plasma to clot after an excess of thromboplastin and an optimal concentration of calcium.
Thrombophilia National Haemophilia Director
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
SCREENING COAGULATION STUDIES When & when NOT to do them.
Russia, Tel/fax: (3822) Tomsk Belinskogo str. 38 www. mednord-t.ru.
In this exercise, two tests will be performed to screen for defective clotting factors. The formation of thrombin in the plasma samples will be inhibited.
Lt Col T Woolley FRCA RAMC Surg Lt Cdr Catherine Doran MRCS PGCAES RN Surg Capt M Midwinter DipAppStats MD FRCS RN NATO Medical Conference Royal Centre.
Proposed algorithm for approval of human TSE tests in Europe.
FDA/PPTA Workshop: Risk Mitigation Strategies to Address Procoagulant Activity in Immune Globulin Products Dorothy Scott, M.D. Mikhail Ovanesov, Ph.D.
M. Ninivaggi, R. Apitz-Castro, Y. Dargaud,
Investigation of Haemostasis MS. c. program Lab-9.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Activated Partial Thromboplastin Time (aPTT)
Hemophilia Management: Joint Bleeds and Prophylaxis.
Laboratory Testing in Coagulation Coagulation Keri Brophy-Martinez.
Tests of Hemostasis Path 430/826 David Lillicrap Department of Pathology and Molecular Medicine Queen’s University, Kingston, Canada.
Intrinsic pathway Extrinsic pathway Common pathway The extrinsic pathway was required the addition of an exogenous trigger (originally provided by tissue.
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Rivaroxaban: A Comparison of Once- and Twice-daily Dosing in Patients Undergoing Total Hip Replacement.
Hemostasis Is a complex process which causes the bleeding process to stop. It refers to the process of keeping blood within a damaged blood vessel. Dependent.
Chapter 17 Coagulation Testing
Systemic anticoagulation during ECMO is intended to control thrombin generation and limit the risk for thrombotic and hemorrhagic complications.
Nguyen Ngoc Tu1,2, Marie-Christine Morel-Kopp3, Chris Ward 3, Robert G
One-Stage Quantitative
MLAB Coagulation Keri Brophy-Martinez
Between-technician Variation upon Estimation of Electrophoresis Peaks of Gammopathy Patients Pedro Medina Escobar, Julie Sottas, Anne Conus, Urs Nydegger,
Anticoagulation Monitoring Shouldn’t We Validate?
Elvira Maličev Blood Transfusion Centre of Slovenia
One Stage Factor V Assay
General Approach of Haemostasis
Activation of coagulation and fibrinolytic pathways in patients with left ventricular assist devices  Talia Spanier, MDa, Mehmet Oz, MDa, Howard Levin,
Effects of rivaroxaban and apixaban on routine coagulation screening tests Sean Platton1*, Louise Bowles1, Peter MacCallum2 The Royal London Hospital,
Workflow Benefits of Test-specific thresholds on Sysmex CS analysers
Monitoring and Treatment of Coagulation Disorders in End-Stage Liver Disease Visc Med 2016;32: DOI: / Fig. 1. On the left side,
Hypercoagulable States
Evaluation of APTT clot waveform analysis by IL ACL TOP® in patients with Haemophilia and comparison to clot waveform analysis with MDA® 180 P-TH-568 Aghighi.
Activation of factor XI by products of prothrombin activation
Tissue-Specific Expression of Functional Platelet Factor XI Is Independent of Plasma Factor XI Expression by Chang-jun Hu, Frank A. Baglia, David C.B.
Activated Partial Thromboplastin Time (aPTT)
Kinetics and mechanics of clot contraction are governed by the molecular and cellular composition of the blood by Valerie Tutwiler, Rustem I. Litvinov,
Vessel wall BAMBI contributes to hemostasis and thrombus stability
Recombinant factor VIIa restores aggregation of αIIbβ3-deficient platelets via tissue factor–independent fibrin generation by Ton Lisman, Jelle Adelmeijer,
Response: Platelets do not generate activated factor XII—how inappropriate experimental models have led to misleading conclusions by Niklas Boknäs, Lars.
Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk by Alisa S. Wolberg, Dougald.
by Cornelis van 't Veer, Neal J. Golden, and Kenneth G. Mann
by Matthew F. Whelihan, Vicentios Zachary, Thomas Orfeo, and Kenneth G
Apoptotic Vascular Endothelial Cells Become Procoagulant
Mechanism of factor VIIa–dependent coagulation in hemophilia blood
Effect of rivaroxaban on thrombin generation in vivo
Perioperative factor concentrate therapy
The Use of Global Assays to Monitor Emicizumab Prophylactic Therapy in Patients with Hemophilia A with Inhibitors Mid-Atlantic Region III HTCs Annual.
Principles of Coagulation Screening II
by Sarah M. Nordstrom, Brian A. Holliday, Brandon C. Sos, James W
Reduced prothrombinase inhibition by tissue factor pathway inhibitor contributes to the factor V Leiden hypercoagulable state by Jeremy P. Wood, Lisa M.
Hemostasis and Coagulation
Presentation transcript:

Thrombin Generation Test (TGT) & Rotational Thromboelastography (ROTEM™) and its use in assessing Severe Haemophilia A phenotype The classification and diagnosis of Haemophilia A (HA) is commonly based on one stage clotting assays of factor VIII (FVIII:C). Patients with severe HA have a FVIII:C of less than 1IU/dL. Based on clinical observations, 10-15% of severe HA patients demonstrate a mild clinical phenotype 1. Recent published studies indicate that the measurement of prothrombotic markers and global parameters of haemostasis such as thrombin generation test (TGT) and thromboelastography may be useful predictors of clinical phenotype in severe HA 2,3. TGT is an in-vitro laboratory test that is performed on platelet poor plasma (PPP) or platelet rich plasma (PRP) using either a chromogenic or fluorogenic substrate to measure the generation of thrombin after the addition of re-lipidated tissue factor and CaCl 2. 4 Rotational Thromboelastography (ROTEM™) is a global real time measurement of the formation of a fibrin clot in a whole blood sample over a period of time 3. The data generated by TGT and ROTEM™ parameters suggest a wide range of variation in the patient group compared with normal individuals. The majority of patients in this study had received no prophylaxis as children making it difficult to score the true clinical phenotype and thus correlate with the TGT and ROTEM™ parameters. The information gained from ROTEM™ and TGT compared to conventional laboratory monitoring suggests a need for more comprehensive evaluation of these tools in the context of physiological and interpersonal variation of a thrombin generation. 1.Aledort, L.M., R.H. Haschmeyer, and H. Pettersson, A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med, (4): p Beltran-Miranda, C.P., et al., Thrombin generation and phenotypic correlation in haemophilia A. Haemophilia, (4): p Sorenson B, Johansen P, Christiansen K, Woelke M, Ingerslav J. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J. Thromb. Haemost. 1 (2003), pp. 551– Hemker H C, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: TGT 80  L of PPP was added to 20mL initiation reagent (containing tissue factor (TF) (Innovin, DadeBehring, Germany), and phospholipid vesicles (PS/PC/PE) to obtain a final concentration 1pM TF and 4  M PS/PC/PE). For PRP, 80  L of PRP was added to 20mL initiation reagent (containing TF with final concentration of 0.5pM) After incubating at 37C o,  l starting reagent (containg100 mM CaCl 2 and 2.5mM Z-Gly- Gly-Arg-AMC.HCL fluorogenic substrate (Bachem, UK)) was added to each well. Relative fluorescent unit (RFU) were measured at 30 second intervals for one hour using a SpectraMax Gemini XS plate reader (Molecular Devices, UK) at excitation wavelength of 390nm and reading wavelength of 460nm. The data was exported into an excel™ file and the amount of thrombin generated was calculated according to the method by Hemker & Beguin, 1999 and Hemker et al 2000 to determine the amount of free thrombin in a continuous TGT with a fluorogenic substrate. ROTEM™ Citrated whole blood (CWB) was allowed to stand for 30 minutes before testing. 300  L of CWB was pipetted into a cup,  l TF (final concentration 0.35pM) was added and recalcified with 20  L 0.2MCaCl 2 as described by Sorenson. Prothrombothic Markers We have also measured intrinsic and extrinsic plasma clotting proteins, prothrombotic factors including: Protein C (Pro Clot, Instrumentation Laboratory (IL), Milan; Italy), protein S (HemosIL) and anti-thrombin (In-house assay); Activated protein C ratio (APCr), factor V Lieden (Arg506Glu) and prothrombin gene (G20210A ) mutation analysis (Third Wave™ Invader ®). Haemophilia A patients generate less thrombin than normal individuals in a rate dependent (on FVIII) manor. This is because of their inability to form the intrinsic Xase complex. It is apparent that very small amounts of FVIII, below those detectable in conventional FVIII assays, can result in significant amounts of thrombin generation. Hence, some factors, which may cause thrombophilic status, might modulate the bleeding tendency of severe haemophiliacs. Clinical presentation can be regarded as a function of the altered thrombo-haemoragic balance due to the action of many intervening factors. Therefore, it is conceivable that the presence of an abnormality i.e. prothrombotic facrors, may mitigate the clinical phenotype. High plasma concentration of coagulation proteins, such FIX or FXI, is shown to increase the risk of thrombosis in normal individuals. Presence other thrombotic factors such as factor V Leiden and prothrombin G202010A, on the other hand, may also lessen the severity of bleeding tendency in some haemophiliacs. Acknowledgements – Katharine Dormandy Haemophilia Centre & Dr Sanj Raut (NIBSC, Potters Bar, UK for the EXCELL™ spreadsheet to calculate the TGT curves TGT (parameters were expressed as percentage of normal) CTI containing PPP: AUC=12%-67%, mean=41%; Peak Height (PH)=6%-47%, mean=22%; time to peak (TP) expressed in minutes=11-56min, mean=22 CTI containing PRP: AUC=7%-68%, mean=35%; PH=7%-47%, mean=28%; TP=37-61min, mean=50min There was no correlation between TGT parameters in PPP and PRP (r=0.055) S Aghighi, A Riddell, P Chowdary, P Lilly, A Griffioen, E G Tuddenham. The Royal Free NHS Hospital, Pond Street, London NW3 2QG, U.K. Introduction Results Aim The aim of this study was to adapt the use of global assays –flurogenic thrombin generation tests and thromboelastography using ROTEM™, as a diagnostic tool to predict heterogeneity amongst these individuals Subjects and Samples subjects Thirty four patients with severe HA aged years with no inhibitor. Eighteen normal individuals. Ethical approval from the Royal Free Hospital Ethics committee. Informed consent obtained from patients and normal individuals. Samples Blood sample was drawn into citrate Monovettes (Sarstedt; 0.106M trisodium citrate) with and without corn trypsin inhibitor (CTI) giving final concentration of 20  g/ml. PRP was obtained by centrifuging samples for 12min at 150g. PPP was obtained by centrifuging samples for 15min at 2500g. After separating upper two third of plasma; samples centrifuged for further 15min at 2500g. PRP platelet count was adjusted by PPP at 150 x 10 9 /l Methods ROTEM™ CWB with CTI: AUC range 42-67, mean = 52, MaxVel (mm/min) range from , mean 3.8; tMaxVel (min)=10-46, mean=24. CWB without CTI: MaxVel=3-7.3mm/min, mean=4.9; tMaxVel= min mean=17.4 There was correlation between ROTEM parameters of WCB with CTI and WCB (r=0.7) The standard deviation in peak height thrombin generation was 21.2% with the range between % and coefficient of variation of 47%. The time to peak shows a range of min, standard deviation of 12.7%, and coefficient of variation of 55%. ROTEM parameters show similar variation between the group of severe haemophiliacs we investigated tested. FVIII<1 IU Figure 2: TGT; Peak Height in PPP with and without CTI in severe Haemophilia A. Figure 1: TGT parameters in severe Haemophilia A ; PPP and PRP with CTI expressed as percentage of normal Figure 3: ROTEM™; MaxVel(mm/min) in severe Haemophilia A CWB with and without CTI. Prothrombotic Results Two individuals (5.9%) had heterozygous FV Leiden mutation. Two individuals (5.9%) had heterozygous FII (G20210A ) mutation. Four individuals (11.8%) had below normal protein S, three low AT, and two low protein C. Twelve individuals (35%) had low FXI (52-69 IU) normal range IU. One individual (3%) had low FX. Results Discussion Conclusion References Severe HA PPP+CTI Range PRP+CTI Range AUC (%) Peak Height (%) Time to Peak (min) PH Severe HA ROTEM™ CWB+CTI Range CWB Range AUC (mm) Maximum Velocity(mm/min) Time to MaxVel (min)